FindTrial
Sign In

Clinical evaluation of tau-imaging PET tracer [18F]THK-5117 in Alzheimer's disease patients

Clinical evaluation of tau-imaging PET tracer [18F]THK-5117 in Alzheimer's disease patients - Clinical evaluation of [18F]THK-5117 in Alzheimer's disease patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000010522
Enrollment
17
Registered
2013-05-01
Start date
2013-06-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer&#39

Interventions

[18F]THK-5117 and [11C]PiB PET scans will be performed in 8 healthy normal subjects and 8 Alzheimer&#39
s disease patients. Both PET scans will be performed within 3 months interval. [18F]THK-5117 PET study: After 185 MBq of [18F]THK-5117 will be intravenously injected, dynamic PET images of the brai

Sponsors

Tohoku University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Healthy normal subjects without cognitive impairment or cerebrovascular lesion, and probable Alzheimer's disease patients (NINCDS-ADRDA criteria)

Exclusion criteria

Exclusion criteria: Subjects with neuropsychiatric diseases other than Alzheimer's disease, subjects with severe cardiac abnormalities, and subjects with pacemaker or metal device in the body.

Design outcomes

Primary

MeasureTime frame
1. Regional [18F]THK-5117 retention in the brain, referenced to cerebellar cortex 2. Regional [11C]PiB retention in the brain, referenced to cerebellar cortex 3. Effective dose after administration of [18F]THK-5117—

Countries

Japan

Contacts

Public ContactNobuyuki Okamura

Tohoku University School of Medicine Department of Pharmacology

nookamura@med.tohoku.ac.jp022-717-8056

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026